Precision Cancer Medicine
Search All News
Spotlighting new research from the Momen-Heravi lab on immunotherapy response in head and neck cancer and other solid tumor types.
A new study by Elham Azizi and Ben Izar shows a new technique to study cancer tissues archived in biobanks, increasing the variety of samples for analysis and the discovery of biomarkers.
An international team, led by cancer center researchers, has demonstrated the potential of a new, innovative approach to prostate cancer treatment.
Exciting new clinical investigations, including results of the ALPINE study, show promising, more effective treatment for patients with CLL.
- September 27, 2021
"Precision cancer medicine needs to be envisioned as understanding how cancer works, which goes far beyond individual gene mutations." Read Dr. Bass' Disruptors column for the HICCC.
- June 24, 2021
In our Disruptors column, Gordana Vunjak-Novakovic discusses groundbreaking work between engineers and cancer researchers to accelerate personalized therapeutics and better understand the disease.
- June 5, 2021
Results of a new phase 2 clinical trial demonstrate the potential of targeted therapy in combination with chemotherapy to treat patients with uterine leiomyosarcoma.
- June 3, 2021
Five teams of researchers are awarded pilot grants to conduct innovative basic science, translational, and clinical research across multiple diseases.
- May 11, 2021
In a new study by Adam Bass, MD, scientists have found that many esophageal cancers turn on ancient viral DNA embedded in our genome, a finding that could lead to improvements in immunotherapy.
Source:CUIMC NewsroomOctober 29, 2020
Adam Bass, MD, joins the HICCC as the founding director of the Center for Precision Cancer Medicine and director of gastrointestinal oncology.